Across TCGA pan-cancer cohorts, GLT6D1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GLT6D1 data layer compared with 15 for mass-spec protein.
The strongest signal is observed in small cell lung cancer (SCLC), where higher GLT6D1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GLT6D1 expression acts as an unfavorable survival marker, although some lineages such as COAD show a favorable association.
SCLC, ESCA, and HNSC are the cancer types where GLT6D1 Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.